ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) complied with federal securities laws. On July 22, 2025, Telix disclosed that the Company “received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Following th ...